Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (281-290 of 484) with videos related to

Pageof 49
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|February 28, 2020
Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention TrialKathleen Torkko, Cathee Till, Catherine M Tangen, et al.
Therapeutic Advances in Medical Oncology|November 19, 2010
COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCERTanya B Dorff, Cathy M Tangen, E David Crawford, et al.
The American Journal of Managed Care|May 12, 2010
Preliminary treatment considerations among men with newly diagnosed prostate cancerSteven B Zeliadt, Carol M Moinpour, David K Blough, et al.
JAMA Oncology|November 7, 2024
Long-Term Adverse Effects and Complications After Prostate Cancer TreatmentJoseph M Unger, Cathee Till, Catherine M Tangen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 13, 2006
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trialZhihong Gong, Marian L Neuhouser, Phyllis J Goodman, et al.
Oncotarget|October 20, 2023
Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancerDevalingam Mahalingam, Salih Hanni, Anthony V Serritella, et al.
Oncotarget|June 19, 2023
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancerDevalingam Mahalingam, Salih Hanni, Anthony V Serritella, et al.
The Journal of Urology|August 18, 2009
Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosisJoke Beuten, Dawn Garcia, Timothy C Brand, et al.
The Journal of Urology|May 28, 2013
Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO GuidelineIan M Thompson, Richard K Valicenti, Peter Albertsen, et al.
The Journal of Urology|January 15, 2013
The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculatorDonna P Ankerst, Cathee Till, Andreas Boeck, et al.
Pageof 49

Showing results (281-290 of 484) with videos related to

Sort By:
Pageof 49
Cancer Prevention Research (Philadelphia, Pa.)|February 28, 2020
Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention TrialKathleen Torkko, Cathee Till, Catherine M Tangen, et al.
Therapeutic Advances in Medical Oncology|November 19, 2010
COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCERTanya B Dorff, Cathy M Tangen, E David Crawford, et al.
The American Journal of Managed Care|May 12, 2010
Preliminary treatment considerations among men with newly diagnosed prostate cancerSteven B Zeliadt, Carol M Moinpour, David K Blough, et al.
JAMA Oncology|November 7, 2024
Long-Term Adverse Effects and Complications After Prostate Cancer TreatmentJoseph M Unger, Cathee Till, Catherine M Tangen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 13, 2006
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trialZhihong Gong, Marian L Neuhouser, Phyllis J Goodman, et al.
Oncotarget|October 20, 2023
Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancerDevalingam Mahalingam, Salih Hanni, Anthony V Serritella, et al.
Oncotarget|June 19, 2023
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancerDevalingam Mahalingam, Salih Hanni, Anthony V Serritella, et al.
The Journal of Urology|August 18, 2009
Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosisJoke Beuten, Dawn Garcia, Timothy C Brand, et al.
The Journal of Urology|May 28, 2013
Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO GuidelineIan M Thompson, Richard K Valicenti, Peter Albertsen, et al.
The Journal of Urology|January 15, 2013
The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculatorDonna P Ankerst, Cathee Till, Andreas Boeck, et al.
Pageof 49